Nova Biomedical Launches CE-Marked StatStrip Lactate, Hemoglobin, and Hematocrit Point-of-Care Meter System

FOR IMMEDIATE RELEASE : March 25, 2020
Contact: Doug Curley
(781) 647-3700 ext. 1570
DCurley@novabio.com

Waltham, MA– Nova Biomedical announces the launch of both the StatStrip and StatStrip Xpress2 Lactate, Hemoglobin, and Hematocrit Meter Systems in all CE regulated countries. Both meters provide lactate results in only 13 seconds from a 0.6 microliter capillary blood sample, and hemoglobin and hematocrit results in 40 seconds from a 1.6 microliter capillary blood sample. StatStrip Lac/Hb/Hct meter system can connect to laboratory information systems (LIS) and electronic medical records (EMR) while the Xpress2 Lac/Hb/Hct is designed for applications that do not require connectivity. All results offer excellent correlation to laboratory reference methods and testing with a StatStrip or Xpress2 Lac/Hb/Hct meter system is as easy as glucose self-testing.

StatStrip and StatStrip Xpress2 Lac/Hb/Hct systems offer fast, point-of-care (POC) testing with single-use, disposable biosensors, tiny capillary blood samples, and easy to read, color display screens. The meters enable rapid, affordable lactate, hemoglobin, and hematocrit testing for any size emergency department, intensive care unit, medical unit, as well as in pre-hospital, ambulance and military care situations.

Lactate measurement is used to assess tissue hypoxia during sepsis, trauma and other illnesses. It is also useful in sports medicine and training as an indicator of aerobic conditioning and optimal training intensity level for elite athletes. Unlike other meters, the StatStrip Lac/Hb/Hct and Xpress2 Lac/Hb/Hct meters provide measured, not calculated, results for both Hb and Hct. This real-time accuracy improves clinical decision making for anemia and blood loss monitoring.

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 24 analytes. Nova’s BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,500 people worldwide and has wholly owned subsidiaries located in Australia, Benelux, Brazil, Canada France, Germany, Great Britain, Italy, Japan, Spain, and Switzerland. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.
www.novabiomedical.com